Patient-reported preferences for oral versus intravenous administration for the treatment of cancer: a review of the literature.
OBJECTIVE
The emergence of various modes of administration for cancer treatment, including oral administration, brings into focus the importance of patient preference for administration. The purpose of this research was to evaluate the administration preferences of cancer patients, specifically between oral and intravenous (IV) treatment, as well as the factors contributing to preference.


METHODS
A literature search was conducted in OvidSP to identify research in which the preferences of cancer patients for oral or IV treatment have been evaluated. Data were analyzed in two stages: 1) those articles that directly compared preference between modes of administration were tallied to determine explicit preference for oral or IV treatment; and 2) all attributes associated with patient preference were documented.


RESULTS
Of the 48 abstracts identified as part of the initial OvidSP search, eight articles were selected for full-text review. One article was removed following full-text review, and seven additional articles were identified through a gray literature search, yielding a total of 14 articles for evaluation. In Stage 1, 13 of the 14 articles compared preference, of which eleven articles (84.6%) reported that patients preferred oral treatment over IV, while two (15.4%) stated that cancer patients preferred IV treatment over oral. In Stage 2, the most frequently reported attributes contributing to preference included convenience, ability to receive treatment at home, treatment schedule, and side effects.


CONCLUSIONS
Evidence suggests that oncology patients prefer oral treatment to IV. Rationale for preference was due to a number of factors, including convenience, perception of efficacy, and past experience. Further evaluation should be conducted, given the limited data on patient preference in oncology.
AstraZeneca, Gothenburg, Sweden.
Daniel
D
Eek
Adelphi Values, Boston, MA, USA.
Meaghan
M
Krohe
Adelphi Values, Boston, MA, USA.
Iyar
I
Mazar
AstraZeneca, Macclesfield, UK.
Alison
A
Horsfield
Adelphi Values, Boston, MA, USA.
Farrah
F
Pompilus
Adelphi Values, Boston, MA, USA.
Rachel
R
Friebe
Adelphi Values, Boston, MA, USA.
Alan L
AL
Shields
literature review; mode of administration; oncology; patient preference; treatment